Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Endometrial Atypical HyperplasiaEndometrial Adenocarcinoma
Interventions
DRUG

Megestrol acetate and metformin

Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 3 months.

DRUG

Megestrol acetate

Patients will receive megestrol acetate 160 mg by mouth daily for 3 months.

Trial Locations (5)

200011

Obstetrics and Gynecology Hospital, Fudan University, Shanghai

200032

Fudan University Shanghai Cancer Center, Shanghai

Unknown

Shanghai Changning Maternity & Infant Health Hospital, Shanghai

Shanghai Sixth People's Hospital, Shanghai

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
collaborator

Fudan University

OTHER

collaborator

Shanghai 6th People's Hospital

OTHER

collaborator

Zhejiang Cancer Hospital

OTHER

collaborator

Shanghai Changning Maternity & Infant Health Hospital

OTHER

lead

Xiaojun Chen

OTHER

NCT01968317 - Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma | Biotech Hunter | Biotech Hunter